Beam And Verve Benefit From Buzz Around Base-Editing Therapies

Excitement Around Next-Gen Gene-Editing

 
• By Andrew McConaghie

Companies claim their technologies provide more precise editing as they raise funds, but CRISPR companies remain in the lead.

Sekar Kathiresan
Verve's CEO Sekar Kathiresan. The company is working in partnership with Beam Therapeutics on bringing base edited gene therapies to market. • Source: Verve Therapeutics

More from Business

More from Scrip